# Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

> **NCT00911625** · PHASE4 · COMPLETED · sponsor: **Loyola University** · enrollment: 114 (actual)

## Conditions studied

- Type 2 Diabetes
- Renal Insufficiency

## Interventions

- **DRUG:** 0.5 units/kg daily insulin
- **DRUG:** 0.25 units/kg daily insulin

## Key facts

- **NCT ID:** NCT00911625
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-21
- **Primary completion:** 2011-06-30
- **Final completion:** 2011-06-30
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2017-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911625, "Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00911625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*